hydroxyindoleacetic acid has been researched along with Parkinsonian Disorders in 19 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i." | 1.42 | Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2015) |
| "Treatment with idazoxan counteracted the observed Parkinsonian behaviour in 6-OHDA-lesioned rats and increased the spontaneous open-field activity in control rats." | 1.32 | The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? ( Schmidt, WJ; Srinivasan, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Kaiserova, M | 1 |
| Chudackova, M | 1 |
| Prikrylova Vranova, H | 1 |
| Mensikova, K | 1 |
| Kastelikova, A | 1 |
| Stejskal, D | 1 |
| Kanovsky, P | 1 |
| Gruden, MA | 1 |
| Davydova, TV | 1 |
| Narkevich, VB | 1 |
| Fomina, VG | 1 |
| Wang, C | 1 |
| Kudrin, VS | 1 |
| Morozova-Roche, LA | 1 |
| Sewell, RD | 1 |
| Santiago, RM | 1 |
| Tonin, FS | 1 |
| Barbiero, J | 1 |
| Zaminelli, T | 1 |
| Boschen, SL | 1 |
| Andreatini, R | 1 |
| Da Cunha, C | 2 |
| Lima, MM | 2 |
| Vital, MA | 2 |
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Steiniger, A | 1 |
| Klioueva, A | 1 |
| Negron, GE | 1 |
| Lormand, L | 1 |
| Park, JY | 1 |
| Bishop, C | 1 |
| Boulet, S | 1 |
| Mounayar, S | 1 |
| Poupard, A | 1 |
| Bertrand, A | 1 |
| Jan, C | 1 |
| Pessiglione, M | 1 |
| Hirsch, EC | 1 |
| Feuerstein, C | 1 |
| François, C | 1 |
| Féger, J | 1 |
| Savasta, M | 1 |
| Tremblay, L | 1 |
| Nowak, P | 1 |
| Kostrzewa, RA | 1 |
| Skaba, D | 1 |
| Kostrzewa, RM | 1 |
| Kurian, MA | 1 |
| Li, Y | 1 |
| Zhen, J | 1 |
| Meyer, E | 1 |
| Hai, N | 1 |
| Christen, HJ | 1 |
| Hoffmann, GF | 1 |
| Jardine, P | 1 |
| von Moers, A | 1 |
| Mordekar, SR | 1 |
| O'Callaghan, F | 1 |
| Wassmer, E | 1 |
| Wraige, E | 1 |
| Dietrich, C | 1 |
| Lewis, T | 1 |
| Hyland, K | 1 |
| Heales, S | 2 |
| Sanger, T | 1 |
| Gissen, P | 1 |
| Assmann, BE | 1 |
| Reith, ME | 1 |
| Maher, ER | 1 |
| Chao, OY | 2 |
| Huston, JP | 2 |
| von Bothmer, A | 1 |
| Pum, ME | 2 |
| Moreira, CG | 1 |
| Barbiero, JK | 1 |
| Ariza, D | 1 |
| Dombrowski, PA | 1 |
| Sabioni, P | 1 |
| Bortolanza, M | 1 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| Nikolaus, S | 1 |
| Ricaurte, GA | 1 |
| Yuan, J | 1 |
| Hatzidimitriou, G | 1 |
| Cord, BJ | 1 |
| McCann, UD | 1 |
| Foster, SB | 1 |
| Wrona, MZ | 1 |
| Han, J | 1 |
| Dryhurst, G | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Crawley, F | 1 |
| Rudge, P | 1 |
| Diepold, K | 1 |
| Schütz, B | 1 |
| Rostasy, K | 1 |
| Wilken, B | 1 |
| Hougaard, P | 1 |
| Güttler, F | 1 |
| Romstad, A | 1 |
| Birk Møller, L | 1 |
| Struve, MF | 1 |
| McManus, BE | 1 |
| Wong, BA | 1 |
| Dorman, DC | 1 |
| Nagamitsu, S | 1 |
| Matsuishi, T | 1 |
| Yamashita, Y | 1 |
| Yamada, S | 1 |
| Kato, H | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cerebral Autoregulation in Patients With Aneurysmal SubArachnoid Haemorrhage[NCT03987139] | 45 participants (Anticipated) | Interventional | 2019-06-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 other studies available for hydroxyindoleacetic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
Topics: Diagnosis, Differential; Humans; Hydroxyindoleacetic Acid; Multiple System Atrophy; Parkinson Diseas | 2021 |
Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms.
Topics: Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Hydroxyindoleacetic Acid; Male; Mice; | 2015 |
The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Depressive Disor | 2015 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Di | 2008 |
Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorocebus aethiops; Corpus Striatum; Di | 2008 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 2010 |
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.
Topics: Brain; Cell Line, Transformed; Child; Child, Preschool; Cohort Studies; Dopamine Plasma Membrane Tra | 2011 |
Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Res | 2011 |
Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopaminergic Neurons; Exploratory Behavior; Hyd | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str | 2002 |
The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Aromatic Amino Acid Decarboxylase Inhibitors; Bo | 2003 |
The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Anima | 2004 |
Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Brain Chemistry; Catalepsy; Disease Mod | 2004 |
Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency.
Topics: Adult; Biopterins; Brain; Brain Diseases, Metabolic; Electroencephalography; Epilepsy; Female; Heroi | 2004 |
Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections.
Topics: Animals; Antiparkinson Agents; Central Nervous System Viral Diseases; Child, Preschool; DNA Mutation | 2005 |
Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; gamma-Amin | 2007 |
Extrapontine myelinolysis with parkinsonism after rapid correction of hyponatremia: high cerebrospinal fluid level of homovanillic acid and successful dopaminergic treatment.
Topics: Antiparkinson Agents; Basal Ganglia; Child; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1999 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do | 2001 |